• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

    2/14/24 6:45:55 PM ET
    $CRVL
    Specialty Insurers
    Finance
    Get the next $CRVL alert in real time by email
    SC 13G/A 1 d759458dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 27)*

     

     

    CorVel Corporation

    (Name of Issuer)

    Common Stock, $0.0001 Par Value Per Share

    (Title of Class of Securities)

    221006109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Page 1 of 4 Pages)


    CUSIP NO. 221006109    13G/A    Page 2 of 4 Pages

     

     1.   

     NAMES OF REPORTING PERSONS

     

     V. Gordon Clemons

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.    

     SOLE VOTING POWER

     

     900,000(1)

       6.   

     SHARED VOTING POWER

     

     323,534(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     900,000(1)

       8.   

     SHARED DISPOSITIVE POWER

     

     323,534(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,223,534

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     7.15%

    12.  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    Represents 900,000 shares of Common Stock held directly by V. Gordon Clemons, as an individual.

    (2)

    Represents 323,534 shares of Common Stock held directly by the Marie Eve Clemons Living Trust, of which Mr. Clemons’ spouse serves as a trustee. Mr. Clemons may be deemed to have shared voting and/or dispositive power over these shares.


    CUSIP NO. 221006109    13G/A    Page 3 of 4 Pages

     

    Item 1(a).

    Name of Issuer:

    CorVel Corporation (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    5128 Apache Plume Road, Suite 400

    Fort Worth, TX 76109

     

    Item 2(a).

    Name of Person Filing:

    V. Gordon Clemons (“Mr. Clemons”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    c/o CorVel Corporation

    5128 Apache Plume Road, Suite 400, Fort Worth, TX 76109

     

    Item 2(c).

    Citizenship

    United States of America

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 Par Value Per Share

     

    Item 2(e).

    CUSIP Number:

    221006109

     

    Item 3.

    If This Statement is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a)   ☐    Broker or dealer registered under section 15 of the Act;
             (b)   ☐    Bank as defined in section 3(a)(6) of the Act;
      (c)   ☐    Insurance company as defined in section 3(a)(19) of the Act;
      (d)   ☐    Investment company registered under section 8 of the Investment Company Act of 1940;
      (e)   ☐    An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
      (f)   ☐    An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
      (g)   ☐    A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
      (h)   ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
      (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j)   ☐    A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
      (k)   ☐    Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

    If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Not Applicable

     

    Item 4.

    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

             (a)    Amount Beneficially Owned:    1,223,534
      (b)    Percent of Class:    7.15%


    CUSIP NO. 221006109    13G/A    Page 4 of 4 Pages
              (c)    Number of shares as to which the person has:   

     

     

    (i)

      

    Sole power to vote or to direct the vote:

         900,000                 

           

     

    (ii)

      

    Shared power to vote or to direct the vote:

         323,534     
     

    (iii)

      

    Sole power to dispose or to direct the disposition of:

         900,000     
     

    (iv)

      

    Shared power to dispose or to direct the disposition of:

         323,534     

     

     

    As of December 31, 2023, Mr. Clemons beneficially owned 1,223,534 shares of the Issuer’s Common Stock, including 900,000 shares owned directly by him and 323,534 shares owned directly by the Marie Eve Clemons Living Trust, of which Mr. Clemons’ spouse serves as trustee.

     

     

    Mr. Clemons’ beneficial ownership represents 7.15% in the aggregate of the Issuer’s outstanding Common Stock.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. ☐

    Not Applicable

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not Applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024       /s/ V. Gordon Clemons
          Name: V. Gordon Clemons

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, Provided, however, That a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d–7 for other parties for whom copies are to be sent.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

    Get the next $CRVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CRVL
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $CRVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • CorVel Earns 2025 Great Place To Work Certification™

      FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL) is proud to be Certified™ by Great Place To Work® for the fifth year in a row. The prestigious award is based entirely on what current employees say about their experience working at CorVel. Great Place To Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation. "We are very pleased to be recognized as a Great Place To Work for a 5th consecutive year. CorVel is committed to being an organization where people can learn, grow, and advance, and we are grateful for the team members

      2/25/25 7:05:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Corporation Appoints Sarah Scott as Executive Vice President of Product

      FORT WORTH, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ: CRVL), a national provider of risk management solutions, today announced the promotion of Sarah Scott to Executive Vice President of Product. In her expanded role, Sarah will be responsible for defining and driving the overall product vision and strategy, from ideation to launch and ongoing optimization. Sarah's leadership will ensure the company continues to deliver innovative solutions that create value and meet the evolving needs of its partners. Throughout her 25 years with CorVel, Sarah has been instrumental in the company's success. In her previous role as Vice President of Network Solutions, Sarah playe

      2/13/25 7:25:00 AM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    SEC Filings

    See more

    $CRVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CRVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 144 filed by CorVel Corp.

      144 - CORVEL CORP (0000874866) (Subject)

      2/11/25 5:22:53 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 10-Q filed by CorVel Corp.

      10-Q - CORVEL CORP (0000874866) (Filer)

      2/6/25 4:30:25 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 144 filed by CorVel Corp.

      144 - CORVEL CORP (0000874866) (Subject)

      2/6/25 4:28:31 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Vice President of Accounting Yoss Jennifer

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 7:02:08 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Chief Information Officer Shishin Maxim

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 6:30:11 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Chief Information Officer Shishin Maxim

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 6:27:44 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/14/24 6:45:55 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 5:02:29 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 4:05:36 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Leadership Updates

    Live Leadership Updates

    See more
    • CorVel Corporation Appoints Sarah Scott as Executive Vice President of Product

      FORT WORTH, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ: CRVL), a national provider of risk management solutions, today announced the promotion of Sarah Scott to Executive Vice President of Product. In her expanded role, Sarah will be responsible for defining and driving the overall product vision and strategy, from ideation to launch and ongoing optimization. Sarah's leadership will ensure the company continues to deliver innovative solutions that create value and meet the evolving needs of its partners. Throughout her 25 years with CorVel, Sarah has been instrumental in the company's success. In her previous role as Vice President of Network Solutions, Sarah playe

      2/13/25 7:25:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Announces Retirement of V. Gordon Clemons

      FORT WORTH, Texas, Nov. 29, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announces V. Gordon Clemons is electing to retire as a member of the Company's Board of Directors (the "Board") and as Chairman of the Board, effective November 26, 2024, after 37 years of service. Clemons founded CorVel Corporation in 1988 and has served as Chairman of the Board since the Company went public in 1991. Effective upon Clemons' retirement, Michael G. Combs, the Company's President and Chief Executive Officer, was appointed as the new Chairman of the Board. Clemons has been an advisor to Combs since 2017, and he will continue to be available to Combs as an outside consultant. "Building CorVe

      11/29/24 1:30:00 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Appoints Jeff Gurtcheff Vice President of Enterprise Comp

      FORT WORTH, Texas , Feb. 02, 2022 (GLOBE NEWSWIRE) -- CorVel, a national provider of risk management solutions, has named Jeff Gurtcheff as Vice President of Enterprise Comp. With more than 30 years of experience, Gurtcheff brings a deep understanding of the industry with strategic leadership and management expertise. As Vice President of Enterprise Comp, Gurtcheff will refine product vision and strategy related to corporate goals and manage resources responsible for regulatory compliance, claims handling, quality, and standards and procedures. His position will also support product line profit growth by developing improved processes, risk management practices, and analytical reporting.

      2/2/22 7:08:00 AM ET
      $CRVL
      Specialty Insurers
      Finance